Skip to main content
SpringerLink
Log in

Carcinome hépato-cellulaire

  • Chapter
Les cancers digestifs

Part of the book series: Oncologie Pratique ((ONCOLPRAT))

  • 321 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594–606

    CAS  PubMed  Google Scholar 

  2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745–50

    Article  CAS  PubMed  Google Scholar 

  3. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349: 1436–42

    CAS  PubMed  Google Scholar 

  4. La Vecchia C, Lucchini F, Franceschi S et al. (2000) Trends in mortality from primary liver cancer in Europe. Europ J Cancer 36: 909–15

    Google Scholar 

  5. Edmonson HA, Steiner PE (1954) Primary carcinoma of the liver. A study of 100 cases among 48 900 necropsies. Cancer 7: 462–503

    Google Scholar 

  6. Gibson JB, Sobin PE (1978) Histological typing of tumor of the liver, biliary tract and pancreas. In: International classification of tumors. Geneva World health Organization

    Google Scholar 

  7. Bruix J, Sherman M, Llovet JM et al. for the EASL panel of experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35: 421–30

    Article  CAS  PubMed  Google Scholar 

  8. Hermanek P et al. (1998) TNM Atlas. Guide illustré de la classification TNM/pTNM des tumeurs malignes. 4e édition. Paris: Springer-Verlag

    Google Scholar 

  9. Vauthey JN, Lauwers GY, Esnaola NF et al. (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20: 1527–36

    Article  PubMed  Google Scholar 

  10. Okuda K, Ohtushi T, Obata H et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56: 918–28

    CAS  PubMed  Google Scholar 

  11. The Cancer of the Liver Italian Program (CLIP) investigators (1998) A new prognostic system for hepatocellular carcinoma. Hepatology 28: 751–5

    Article  Google Scholar 

  12. The Cancer of the Liver Italian Program (CLIP) investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31: 840–5

    Google Scholar 

  13. Chevret S, Trinchet JC, Mathieu D et al. for the Groupe d’étude et de traitement du carcinome hépato-cellulaire (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31: 133–41

    Article  CAS  PubMed  Google Scholar 

  14. Calvet X, Bruix J, Bru C et al. (1990) Natural history of hepatocellular carcinoma in Spain. Five years experience in 249 cases. J Hepatol 10: 311–7

    Article  CAS  PubMed  Google Scholar 

  15. Attali P, Prod’homme S, Pelletier G et al. (1987) Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 59: 2108–11

    CAS  PubMed  Google Scholar 

  16. Cottone M, Virdone R, Fusco G et al. (1989) Asymptomatic hepatocellular carcinoma in Child’s A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 96: 1566–71

    CAS  PubMed  Google Scholar 

  17. Devlin J, O’Grady J (1999) Indications for referral and assessment in adult liver transplantation: a clinical guideline. Gut 45(suppl VI): V11–22

    Google Scholar 

  18. Mazzaferro V, Regalia E, Doci R et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693–9

    Article  CAS  PubMed  Google Scholar 

  19. Figueras J, Jaurrieta E, Valls C et al. (1997) Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 25: 1485–9

    Article  CAS  PubMed  Google Scholar 

  20. Llovet JM, Fuster J, Bruix J et al. (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434–40

    Article  CAS  PubMed  Google Scholar 

  21. Poon RT, Fan ST, Lo CM et al. (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235: 373–82

    Article  PubMed  Google Scholar 

  22. Livraghi T, Bolondi L, Buscarini L et al. (1995) No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian cooperative HCC group. J Hepatol 22: 522–6

    Article  CAS  PubMed  Google Scholar 

  23. Livraghi T, Benedini V, Lazzaroni S et al. (1998) Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer 83: 48–57

    Article  CAS  PubMed  Google Scholar 

  24. Lencioni R, Pinto F, Armillota N et al. (1997) Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 7: 514–9

    Article  CAS  PubMed  Google Scholar 

  25. Ohnishi K, Yoshioka H, Fujiwara K (1998) Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 27: 67–72

    Article  CAS  PubMed  Google Scholar 

  26. Lencioni RA, Allgaier HP, Cioni D et al. (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparaison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228: 235–40

    PubMed  Google Scholar 

  27. Scaife CL, Curley SA (2003) Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. Surg Oncol Clin N Am 12: 243–55

    PubMed  Google Scholar 

  28. Livraghi T, Solbiati L, Meloni MF et al. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226: 441–51

    PubMed  Google Scholar 

  29. Izumi R, Shimizu K, Iyobe T et al. (1994) Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20: 295–301

    Article  CAS  PubMed  Google Scholar 

  30. Ono T, Nagasue N, Kohno H et al. (1997) Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 24: S6–18–S6–25

    CAS  PubMed  Google Scholar 

  31. Harnois DM, Steers J, Andrews JC et al. (1999) Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver transpl Surg 5: 192–9

    Article  CAS  PubMed  Google Scholar 

  32. Lau WY, Leung TW, Ho SK et al. (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353: 797–801

    Article  CAS  PubMed  Google Scholar 

  33. Lin SM, Lin CJ, Hsu CW et al. (2004) Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100: 376–82

    Article  CAS  PubMed  Google Scholar 

  34. Takayama T, Sekine T, Makuuchi M et al. (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802–7

    Article  CAS  PubMed  Google Scholar 

  35. Muto Y, Moriwaki H, Saito A (1999) Reduction of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma with. N Engl J Med 340: 1046–7

    Article  CAS  PubMed  Google Scholar 

  36. Nerenstone SR, Ihnde DC, Friedman MA (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15: 1–31

    Article  CAS  PubMed  Google Scholar 

  37. Schachschal G, Lochs H, Plauth M (2000) Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 12: 281–4

    CAS  PubMed  Google Scholar 

  38. Cheng AL, Chen YC, Yeh KH et al. (1996) Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 77: 872–7

    Article  CAS  PubMed  Google Scholar 

  39. Leung TWT, Patt YZ, Lau W et al. (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5: 1676–81

    CAS  PubMed  Google Scholar 

  40. Leung TWT, Tang AM, Zee B et al. (2002) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxotubicin and 5-fluoro-uracil chemotherapy. Cancer 94: 421–7

    CAS  PubMed  Google Scholar 

  41. Mani S, Schiano T, Garcia JC et al. (1998-1999) Phase II trial of tegafur/uracil (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma. Invest New Drugs 16: 279–83

    CAS  PubMed  Google Scholar 

  42. Patt YZ, Hassan MM, Aguayo A et al. (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. Cancer 101: 578–86

    Article  CAS  PubMed  Google Scholar 

  43. Fuchs CS, Clarck JW, Ryan DP et al. (2002) A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 94: 3186–91

    Article  CAS  PubMed  Google Scholar 

  44. Taieb J, Bonyhay L, Golli L et al. (2003) Gemcitabine + oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98: 2664–70

    CAS  PubMed  Google Scholar 

  45. Wall JG, Benedetti J, O’Rourke MA et al. (1997) Phase II trial to topotecan in hepatocellular carcinoma: a southwest oncology group study. Invest New drugs 15: 257–60

    Article  CAS  PubMed  Google Scholar 

  46. O’Reilly E, Stuart KE, Sanz-Altamira PM et al. (2001) A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 91: 101–5

    CAS  PubMed  Google Scholar 

  47. Boige V, Taieb J, Hebbar M et al. (2002) A multicenter phase II study of irinotecan (CPT-11) in patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 20: A607

    Google Scholar 

  48. Schmidinger M, Wenzel C, Locker GJ et al. (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. British J Cancer 85: 1850–2

    CAS  Google Scholar 

  49. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T et al. (1999) Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 46: 1122–5

    CAS  PubMed  Google Scholar 

  50. Chung YH, Song IH, Song BC et al. (2000) Combined therapy consisting in intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88: 1986–91

    CAS  PubMed  Google Scholar 

  51. Pelletier G, Roche A, Ink O et al. (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11: 181–4

    Article  CAS  PubMed  Google Scholar 

  52. Groupe d’étude et de traitement du carcinome hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma N Engl J Med 332: 1256–61

    Google Scholar 

  53. Pelletier G, Ducreux M, Gay F et al. (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29: 129–34

    Article  CAS  PubMed  Google Scholar 

  54. Llovet JM, Real MI, Montaña X et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734–9

    Article  PubMed  Google Scholar 

  55. Lo CM, Ngan H, Tso WK et al. (2002) Randomised controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164–71

    Article  CAS  PubMed  Google Scholar 

  56. Cammá C, Schepis F, Orlando A et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224: 47–54

    PubMed  Google Scholar 

  57. Llovet JM, Bruix J (2003) Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429–42

    Article  CAS  PubMed  Google Scholar 

  58. Spreafico C, Marchiano A, Regalia E et al. (1994) Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 92: 687–90

    Google Scholar 

  59. Lee HS, Kim KM, Yoon JH et al. (2002) Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 20: 4459–65

    PubMed  Google Scholar 

  60. Koda M, Murawaki Y, Mitsuda A et al. (2001) Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 92: 1516–24

    Article  CAS  PubMed  Google Scholar 

  61. Bruix J, Llovet JM, Castelles A et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27: 1578–83

    Article  CAS  PubMed  Google Scholar 

  62. Castells A, Bruix J, Bru C et al. (1995) Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo controlled trial in 120 patients. Gastroenterology 109: 917–22

    Article  CAS  PubMed  Google Scholar 

  63. Riestra S, Rodriguez M, Delgado M et al. (1988) Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 26: 200–3

    Google Scholar 

  64. Cancer of liver programme (1998) Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled. Lancet 352: 17–20

    Google Scholar 

  65. Perrone F, Gallo C, Daniele B et al. (2002) Cancer of Liver Italian Program (CLIP). Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicenter randomised controlled trial. Curr Pharm Dis 8: 1013–9

    CAS  Google Scholar 

  66. Villa E, Ferreti I, Grottola A et al. (2001) Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 84: 881–5

    Article  CAS  PubMed  Google Scholar 

  67. Grimaldi C, Bleiberg H, Gay F et al. (1998) Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organisation for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 16: 411–7

    CAS  PubMed  Google Scholar 

  68. Lai EC, Lau JY, Wu PC et al. (1993) Recombinant interferon alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17: 389–94

    Article  CAS  PubMed  Google Scholar 

  69. Llovet JM, Sala M, Castells L et al. (2000) Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31: 54–8

    CAS  PubMed  Google Scholar 

  70. Kouroumalis F, Skordilis P, Thermos K et al. (1998) Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 42: 442–7

    CAS  PubMed  Google Scholar 

  71. Yuen MF, Poon RTP, Lai CL et al. (2002) A randomised placebo-controlled study of longacting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36: 687–91

    Article  CAS  PubMed  Google Scholar 

  72. Allgaier HP, Klintk E Neustadt T et al. (2003) Octreotid treatment in patients with advanced hepatocellular carcinoma: first results of the randomized pacebo-controlled double-blind Hector trial. Hepatology 33: 760A

    Google Scholar 

  73. Raoul JL, Guyader D, Bretagne JF et al. (1994) Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35: 1782–7

    CAS  PubMed  Google Scholar 

  74. Raoul JL, Guyader D, Bretagne JF et al. (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labelled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26: 1156–61

    CAS  PubMed  Google Scholar 

  75. Stillwagon GB, Order SE, Guse C et al. (1989) 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Grop Study. Int J Radiat Oncol Biol Phys 17: 1123–9

    Google Scholar 

  76. Epstein B, Ettinger D, Leichner PK et al. (1991) Multimodality cisplatin treatment in non resectable alpha-foetoprotein positive hepatoma. Cancer 67: 896–900

    CAS  PubMed  Google Scholar 

  77. Lai RCS, Choi TK, Tong SW et al. (1986) Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial. World J Surg 10: 501–9

    Article  CAS  PubMed  Google Scholar 

  78. Roca EL, Okazaki N, Okada S et al. (1992) Radiotherapy for bone metastases of hepatocellular carcinoma. Jpn J Clin Oncol 22: 113–6

    CAS  PubMed  Google Scholar 

  79. Collier J, Sherman M (1998) Screening for hepatocellular carcinoma. Hepatology 27: 273–8.

    CAS  PubMed  Google Scholar 

  80. Sarasin FP, Giostra E, Hadengue A (1996) Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh A cirrhosis. Am J Med 101: 422–34

    Article  CAS  PubMed  Google Scholar 

  81. Sangiovanni A, Del Ninno E, Fasani P et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126: 1005–14

    Article  PubMed  Google Scholar 

  82. Nishiguchi S, Shiomi S, Nakatani S et al. (2001) Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis Lancet 357: 196–7

    CAS  Google Scholar 

Download references

Authors
  1. V. Boige
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Dominguez-Tinajero
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Boige, V., Dominguez-Tinajero, S. (2006). Carcinome hépato-cellulaire. In: Les cancers digestifs. Oncologie Pratique. Springer, Paris. https://doi.org/10.1007/2-287-30874-1_11

Download citation

  • DOI: https://doi.org/10.1007/2-287-30874-1_11

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-22087-6

  • Online ISBN: 978-2-287-30874-1

Publish with us

Policies and ethics

Search

Navigation